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progression-free survival, overall survival, safety, and PK/
PD relationships were assessed.
Results Objective response rate was 38 % [23 partial 
responses; 95 % confidence interval (CI) 26–52], and 
18 (30 %) patients had stable disease lasting ≥16 weeks. 
Responses occurred in all histologic subtypes. With median 
follow-up of 34 months (95 % CI 32–37), median over-
all survival was 35 months (95 % CI 19–not estimable), 
median progression-free survival was 15 months (95 % CI 
10–20), and median duration of response was 21 months 
(95 % CI 13–46). Most common Grade 3/4 treatment-
related adverse events included hypertension (13 %), pro-
teinuria (8 %), diarrhea (7 %), weight decrease (7 %), and 
fatigue (5 %). PK/PD analyses revealed trends toward 
greater tumor size reduction and response probability with 
higher axitinib plasma exposures.
Conclusions Axitinib appears active and well tolerated 
in patients with various histologic subtypes of advanced 
thyroid cancer, demonstrating durable responses and long 
overall survival. Axitinib may be useful for the treatment of 
advanced thyroid cancer.
Keywords Axitinib · Iodine-refractory · 
Pharmacokinetic · Pharmacodynamic · Thyroid cancer
Introduction
Thyroid cancer was diagnosed in approximately 212,000 
individuals worldwide and resulted in about 35,000 deaths 
in 2008 [1]. Its incidence has increased, on average, by 
58 % in most populations [2]. Despite its rising inci-
dence, thyroid cancer mortality in the European Union has 
declined [3]. Survival is stage-dependent, with a 5-year rel-
ative survival rate of 57.3 % for distant disease [4].
Abstract 
Purpose Axitinib, a potent and selective second-generation 
inhibitor of vascular endothelial growth factor receptors, 
has shown activity in advanced thyroid cancer in a Phase II 
study. We report updated overall survival and pharmacoki-
netic/pharmacodynamic (PK/PD) analyses from the study.
Methods Patients (N = 60) with advanced thyroid can-
cer of any histology for whom iodine-131 (131I) failed 
to control the disease or 131I was not appropriate therapy 
were administered axitinib 5 mg twice daily. Objective 
response rate (primary endpoint), duration of response, 
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Thyroid tumors have elevated levels of vascular endothelial 
growth factor (VEGF) compared with normal thyroid tissue 
[5], suggesting the VEGF pathway as an appropriate therapeu-
tic target. Several tyrosine kinase inhibitors (TKIs) targeting 
the VEGF pathway (e.g., sorafenib [6–11], sunitinib [12–14], 
axitinib [15, 16], vandetanib [17, 18], pazopanib [19], mote-
sanib [20, 21], cabozantinib [22–24], and lenvatinib [25]) have 
been evaluated in patients with advanced thyroid cancer.
Axitinib, a potent and selective second-generation inhib-
itor of VEGF receptors (VEGFRs) [26], is approved in the 
USA, European Union, and elsewhere for the treatment of 
advanced renal cell carcinoma (RCC) after failure of prior 
systemic therapy [27]. The activity of axitinib was previ-
ously reported in a Phase II trial of patients with various 
histologic subtypes of advanced thyroid cancer in whom 
iodine-131 (131I) failed to control the disease or 131I was 
not appropriate therapy [16]. The final clinical results with 
long-term outcomes, including updated overall survival 
(OS), and pharmacokinetic/pharmacodynamic (PK/PD) 
analyses from this trial are reported here.
Materials and methods
Study design
The primary objective of this Phase II study in patients 
with advanced thyroid cancer was to determine the activ-
ity of axitinib as measured by investigator-assessed over-
all objective response rate (ORR) per Response Evaluation 
Criteria in Solid Tumors (RECIST, v. 1.0) [28]. Complete 
response (CR) or partial response (PR) required confirma-
tion at least 4 weeks after the first observation. The second-
ary objectives were to determine OS, progression-free sur-
vival (PFS), duration of response, and safety; obtain blood 
samples for population PK analyses; and explore relation-
ships between clinical response and plasma-soluble pro-
teins (i.e., VEGF and soluble VEGFR2 [sVEGFR2]).
This study was conducted in accordance with the Decla-
ration of Helsinki, International Conference on Harmoniza-
tion Guideline for Good Clinical Practice, study protocol, 
and all applicable local regulatory requirements and laws. 
Each participant provided written informed consent prior to 
inclusion in the study and agreed to comply with the study 
protocol. Study protocol and informed consent forms were 
approved by an institutional review board or independent 
ethics committee. The trial is registered on ClinicalTrials.
gov (NCT00094055).
Patients and assessments
Key patient inclusion/exclusion criteria and assessments 
were previously described [16]. Briefly, the trial enrolled 
adults with advanced thyroid cancer of any histology for 
whom 131I failed to control the disease or 131I was not 
appropriate therapy. Patients had Eastern Cooperative 
Oncology Group performance status 0 or 1, and at least 
one RECIST-defined target lesion not previously externally 
irradiated. Patients with uncontrolled hypertension [i.e., 
baseline blood pressure (BP) >140/90 mm Hg] were ineli-
gible; antihypertensive medications were permitted. Prior 
treatment with antiangiogenic agents was not permitted.
Treatments
Axitinib was administered orally at a starting dose of 
5 mg twice daily without food or drink, other than water, 
for 2 h before and after each dose. Patients tolerating axi-
tinib without treatment-related adverse events (AEs) Grade 
>1 according to the Common Terminology Criteria for 
Adverse Events (CTCAE, v3.0) [29] for any 8-week period 
were permitted a 20 % dose increase, unless responding 
to therapy. Patients developing subjectively intolerable, 
treatment-related Grade 2 AEs (except alopecia) uncon-
trolled by supportive treatment had axitinib interrupted and 
restarted at the same dose after resolution to Grade ≤1 or 
baseline. If resolution did not occur within 4 weeks, axi-
tinib was discontinued.
Patients developing treatment-related Grade 3/4 non-
hematologic AEs (except for alopecia) or treatment-related 
Grade 4 hematologic AEs uncontrolled by supportive treat-
ment had axitinib interrupted. Upon adequate recovery to 
Grade ≤1 or baseline, treatment was resumed at a 20 % 
lower dose. If resolution did not occur within 4 weeks, axi-
tinib was discontinued. Patients with recurring subjectively 
intolerable toxicity resumed axitinib at a 20 % lower dose 
upon adequate recovery. The previous report [16] specified 
a slightly different dose-modification schema that is more 
consistent with the axitinib prescribing information [27]. 
Axitinib was continued until disease progression, unaccep-
table toxicity, or consent withdrawal. Subsequent therapy 
was at the investigator’s discretion.
Plasma pharmacokinetic samples and analysis
Samples (7 mL of whole blood) for population PK analysis 
were collected 15 min before and 1–2 h after the morning 
dose of axitinib (taken in clinic) on days 1 and 29 and every 
8 weeks thereafter. Patients were required to take axitinib 
uninterrupted for ≥3 days before PK blood sample collec-
tion (not applicable on day 1).
Axitinib plasma concentrations were measured using 
validated high-performance liquid chromatography with 
tandem mass spectrometric detection (Charles River Labo-
ratory Preclinical Services, Shrewsbury, MA, USA) [30–
32]. Following population PK analysis, individual post hoc 
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area under the plasma concentration–time curve at steady 
state (AUCss) was calculated as follows:
and
where CL is systemic plasma clearance for axitinib (indi-
vidual post hoc clearance estimated from population PK 
analysis), AUCss-study is the average AUCss across entire 
time on study, and AUCss-cycle1 is the average AUCss during 
cycle 1.
Plasma-soluble protein biomarkers
Plasma samples for measurement of VEGF and sVEGFR2 
levels were collected on day 1 and every 8 weeks thereafter. 
Details of the bioanalytical methodology for measurement 
of plasma-soluble proteins were previously described [16].
Statistical analysis
Sample size was based on a two-stage Simon minimax 
design [33] to evaluate the null hypothesis that the true 
ORR with axitinib was ≤5 % and the alternative hypothesis 
that ORR was ≥20 %, with type I (α) and type II (β) error 
rates of 0.10. Target accrual was 18 patients in stage I, with 
14 additional patients in stage II if one or more confirmed 
responses were observed. Twenty-eight additional patients 
(total of 60) were treated to gain additional safety and 
activity information. Response rate was summarized, and 
confidence interval (CI) calculated using a method based 
on binomial distribution. Kaplan–Meier methods were used 
to estimate the median PFS, duration of response, and OS; 
corresponding CIs were calculated. Thirteen patients con-
tinued axitinib in an ongoing extension, study A4061008 
(ClinicalTrials.gov, NCT00828919), in which only safety 
data were collected. Efficacy and safety data reported here 
for those 13 patients were based on data collected from this 
original trial.
Initial relationships between axitinib exposure and 
change in tumor size, as measured by sum of longest diam-
eter (SLD) of target lesions, were explored using a simple 
linear regression analysis. Patients were stratified by axi-
tinib AUCss (higher or lower than population median), and 
change from baseline in soluble proteins was compared 
using descriptive statistics. Patients were grouped into 
quartiles according to change from baseline in soluble pro-
teins, and the proportion of RECIST responders (± stand-
ard deviation) was assessed.
Logistic regression for probability of PR was performed. 
The probability of achieving PR was assessed as a function 
AUCss-study = average total daily dose during entire time
on study/CL
AUCss-cycle1 = average total daily dose during cycle 1/CL
of AUCss-cycle1. Odds ratio per 1 ng h/mL change in AUC 
was calculated as:
where β was the logistic regression slope coefficient.
Results
Patients and treatment
Baseline characteristics and demographics for the 60 
patients enrolled were previously reported [16]. Briefly, 
median age was 59 years (range 26–84) and 78 % of 
patients were white; histologic subtypes are shown in 
Table 1. The majority (97 %) of patients received prior 
treatment; however, patients had not received prior antian-
giogenic agents. All patients discontinued the study: 20 
experienced insufficient clinical response; 14 planned to 
enroll in the ongoing extension study A4061008 (Clinical-
Trials.gov, NCT00828919); 11 experienced non-fatal AEs; 
nine refused further participation; four died due to cardi-
orespiratory arrest, multiorgan failure, respiratory failure, 
or pneumonia; and two were lost to follow-up. One patient 
planning to enroll in the extension study had an optical 
malignancy and did not participate.
Median duration of axitinib exposure was 11 months 
(range 0.2–47); 30 patients remained on treatment for at 
least 1 year. Median total daily dose of axitinib was 9 mg 
(range 2–15 mg). The axitinib dose was increased (>5 mg 
twice daily) in 24 patients eligible for dose titration, half 
of whom had a subsequent dose reduction. Another 24 
patients had dose reductions.
Clinical activity
Response assessments were unavailable for 14 patients 
because of missing post-baseline scans or indeterminate 
results (i.e., availability of only one or two post-baseline 
scans, which did not allow confirmation of either PR or 
duration of stable disease ≥16 weeks). For purposes of 
calculating ORR, they were considered non-responders. 
The investigator-assessed overall ORR was 38 % (95 % CI 
26–52); no patient had CR, 23 had PR, and 18 (30 %) had 
stable disease lasting ≥16 weeks. Of the 18 patients with 
stable disease, 17 had stable disease lasting ≥30 weeks. 
Compared with our initial ORR analysis [16], five addi-
tional patients had confirmed PR with long-term follow-
up. One patient with PR on day 600 had 22 % reduction in 
tumor size beginning on day 300, and another patient with 
PR on day 835 had 12 % reduction in tumor size beginning 
on day 166 that increased to 29 % on day 499. Responses 
occurred in all histologic subtypes (Table 1).
odds ratio = expβ
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With an estimated median follow-up for survival of 
34 months (95 % CI 32–37), disease progression or death 
had occurred in 37 (62 %) patients. These updated results, 
accounting for additional follow-up, are based on the final 
locked and clean database. These data were preliminarily 
reported [16], based on an active database and shorter fol-
low-up of 16.6 months (95 % CI 15.0–21.2). In the final 
analysis, investigator-assessed median PFS was 15 months 
(95 % CI 10–20; Fig. 1a), median duration of response was 
21 months (95 % CI 13–46; Fig. 1b), and median OS was 
35 months (95 % CI 19 months–not estimable). Figure 1c 
illustrates OS according to histology.
Safety
All-grade, treatment-related AEs (Table 2) occurred in 56 
(93 %) patients; the most frequently reported AEs included 
diarrhea (63 %), fatigue (55 %), nausea (45 %), and hyper-
tension (42 %). Grade 3/4 treatment-related AEs occurred 
in 21 (35 %) patients; the most common were hypertension 
(13 %), proteinuria (8 %), diarrhea (7 %), weight decrease 
(7 %), and fatigue (5 %). Five (8 %) patients experienced a 
total of six treatment-related Grade 4 AEs: reversible pos-
terior leukoencephalopathy syndrome (RPLS) and hyper-
tension (n = 1), proteinuria (n = 2), cerebrovascular acci-
dent (n = 1), and airway obstruction (n = 1). No Grade 
5 (fatal) treatment-related AE was reported. Eight patients 
experienced 18 treatment-related serious AEs (SAEs): 
RPLS, mental status changes, and hypertension (n = 1); 
cerebrovascular accident and headache (n = 1); abdomi-
nal pain (n = 1); hypertension (n = 1); conduction disor-
der, diarrhea, nausea, vomiting, chest pain, and dehydra-
tion (n = 1); atrial fibrillation (n = 1); granuloma, airway 
obstruction, and respiratory tract hemorrhage (n = 1); 
and weakness (n = 1). Hypertension (n = 2) was the only 
treatment-related SAE experienced by more than one 
patient.
Four treatment-related AEs led to permanent axitinib 
discontinuation: headache (Grade 1), cerebrovascular acci-
dent (Grade 4), proteinuria (Grade 2), and weakness (Grade 
unknown). AEs led to axitinib dose reductions in 25 (42 %) 
patients. Diarrhea (10 %), fatigue (10 %), hypertension 
(7 %), and palmar-plantar erythrodysesthesia (5 %) were 
most frequently associated with dose reductions. Hyper-
tension was managed with antihypertensive medication. 
No patients discontinued the study because of hyperten-
sion; BP elevations were generally resolved by the next 
assessment.
Pharmacokinetic/pharmacodynamic analyses
In all, 49 of 60 patients had adequate PK data to calculate 
post hoc AUCss and were included in the PK/PD analy-
ses. Greater reduction in tumor size (Fig. 2), assessed by 
maximum percent change from baseline in SLD of tar-
get lesions, was seen with increasing axitinib AUCss-
cycle1 (r = 0.332; P = 0.0134) and AUCss-study (r = 0.273; 
P = 0.0523). As a measure of inherent axitinib exposure 
(i.e., before dose titration that could occur at or beyond 
8 weeks), AUCss-cycle1 was used as a measure of drug expo-
sure in individual patients for the remaining PK/PD analy-
ses. Figure 3 provides a comparison of steady-state plasma 
exposures in patients who had PR (denoted at 1.0 on the 
y-axis) versus those who did not have PR (denoted at zero 
on the y-axis). These raw data were subjected to logistic 
regression to obtain the overlaid curve, which describes the 
probability of having PR as a function of axitinib plasma 
exposure. This analysis indicated that patients with higher 
axitinib plasma exposure (AUCss-cycle1) had a greater likeli-
hood of obtaining PR.
Table 1  Investigator-assessed objective response to axitinib: overall and by histologic subtype
a
 Lasting ≥16 weeks. Of the 18 patients with stable disease ≥16 weeks, 17 had stable disease ≥30 weeks
b
 95 % confidence interval 26–52
c
 11 patients had the Hürthle cell variant
d
 Insular
e
 Neuroendocrine
Complete response Partial response Stable diseasea Progressive disease Indeterminate Missing
n (%) n (%) n (%) n (%) n (%) n (%)
All patients (N = 60) 0 23 (38)b 18 (30) 5 (8) 9 (15) 5 (8)
Histologic subtype
 Papillary (n = 30) 0 10 (33) 10 (33) 3 (10) 4 (13) 3 (10)
 Follicular (n = 15)c 0 9 (60) 4 (27) 1 (7) 1 (7) 0
 Medullary (n = 11) 0 2 (18) 3 (27) 0 4 (36) 2 (18)
 Anaplastic (n = 2) 0 1 (50) 0 1 (50) 0 0
 Other (n = 2) 0 1 (50)d 1 (50)e 0 0 0
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Fig. 1  Kaplan–Meier curves for a investigator-assessed PFS; b 
investigator-assessed duration of response (DR) among responders; 
and c overall survival (OS) stratified by histologic subtype. Data for 
PFS, DR, and OS were not collected in the axitinib extension study; 
therefore, results for the 13 patients who rolled over to the extension 
study were based on data collected from the original trial. CI confi-
dence interval, NE non-estimable
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Axitinib was previously reported to lead to a 2.8-
fold increase in mean VEGF and 32 % decrease in mean 
sVEGFR2 concentrations that plateau by week 12 [16]. 
In the current analysis, patients with exposure to axitinib 
that was equal to or greater than median AUCss-cycle1 had 
greater median VEGF increases and sVEGFR2 decreases 
(Fig. 4a). When grouped into quartiles according to per-
cent change from baseline in VEGF and sVEGFR2 con-
centrations, higher proportions of responses were observed 
in patients with the greatest increases from baseline in 
VEGF and those with the greatest decreases from baseline 
sVEGFR2 (Fig. 4b). When stratified by the length of time 
patients received axitinib (≥1 vs. <1 year), no differences 
were observed in median VEGF increases or sVEGFR2 
decreases from baseline (data not shown).
Discussion
A 38 % ORR and 21-month median duration of response 
for axitinib 5 mg twice daily is reported in patients with 
advanced thyroid cancer. Although the sample size was 
too small for definitive assessment, follicular histology 
appeared to be most responsive to axitinib (Table 1). Sta-
ble disease lasting ≥16 weeks, as defined by the protocol, 
occurred in an additional 18 (30 %) patients; however, 17 
of those patients had stable disease lasting ≥30 weeks. 
These translated into 15-month median PFS and 35-month 
median OS. Results from another Phase II trial of axitinib 
in patients (N = 52) with 131I-refractory advanced thyroid 
cancer demonstrated a comparable 35 % ORR, 16.1-month 
median PFS, and 27.2-month median OS [15]. These two 
trials consistently demonstrated that axitinib has activity in 
the treatment of advanced thyroid cancer.
Since documented disease progression was not required 
prior to enrollment in this trial, PFS and OS data may be 
difficult to interpret in light of the natural history of meta-
static thyroid cancer. Several randomized placebo-con-
trolled Phase III trials evaluating VEGFR TKIs have now 
been conducted in patients with advanced thyroid cancer 
[11, 17, 24]. Patients receiving placebo in those trials had 
median PFS of 4 months [24] versus 19.3 months [17] for 
medullary thyroid cancer (MTC) with versus without pro-
gressive disease at study entry. Likewise, patients with pro-
gressive differentiated thyroid cancer (DTC) who received 
placebo had median PFS of 5.8 months [11]. In a rand-
omized placebo-controlled Phase II trial, 16 (22 %) of 73 
patients with DTC who received placebo had stable disease 
for a period of 12 months [18]. Whereas median OS has 
not been reported from these placebo-controlled trials, the 
survival analyses may be confounded by crossover to active 
treatment. Several single-arm Phase II trials have evaluated 
VEGFR TKIs [6–10, 12–14, 19–21, 25] for the treatment of 
advanced thyroid cancer (summarized in Online Resource 
1). Only a few trials have reported median OS in patients 
treated with sorafenib: 23 and 38 months in non-progres-
sive papillary thyroid cancer that was chemotherapy-naïve 
or previously treated with chemotherapy [7], respectively, 
and 35 months in progressive DTC [10].
The National Comprehensive Cancer Network 2013 
Clinical Practice Guidelines [34] suggest consideration 
of systemic therapy with small molecule kinase inhibi-
tors for clinically progressive or symptomatic metastatic 
131I-refractory DTC. Additionally, European Society for 
Medical Oncology 2012 Clinical Practice Guidelines [35] 
recommend enrollment in clinical trials with TKIs for 
patients with metastatic DTC. Results from the current 
study suggest that axitinib may be a potential treatment 
option for 131I-refractory advanced DTC that is progres-
sive or symptomatic. In long-term follow-up, the AE profile 
for axitinib was similar to previously reported results [16], 
thus confirming axitinib is well tolerated, with manageable 
toxicities.
The results reported here suggest there is an increased 
likelihood of an objective response in patients with the 
greatest VEGF increases and sVEGFR2 decreases; how-
ever, due to the considerable overlap observed in pro-
portions of responders and change in VEGF/sVEGFR2 
quartiles, these may not be optimal biomarkers to predict 
response to axitinib. A previous study also suggested that 
changes in sVEGFR2 levels after initiation of motesanib 
might predict response in patients with metastatic DTC 
Table 2  Most common treatment-related adverse events
AE adverse event
a
 Reported in ≥20 % of patients
Adverse eventa All grades Grade 3/4
n (%) n (%)
Any treatment-related AE 56 (93) 21 (35)
Diarrhea 38 (63) 4 (7)
Fatigue 33 (55) 3 (5)
Nausea 27 (45) 1 (2)
Hypertension 25 (42) 8 (13)
Weight decrease 19 (32) 4 (7)
Anorexia 18 (30) 0
Stomatitis 18 (30) 0
Dyspepsia 17 (28) 0
Headache 17 (28) 2 (3)
Mucosal inflammation 15 (25) 0
Proteinuria 15 (25) 5 (8)
Palmar-plantar erythrodysesthesia syndrome 13 (22) 1 (2)
Rash 13 (22) 0
Dysgeusia 12 (20) 0
Hoarseness 12 (20) 0
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or MTC [36]. In the current study, patients with higher 
axitinib AUCss-cycle1, a measure of inherent axitinib expo-
sure, had greater reduction in tumor size, probability of 
PR, and greater median VEGF increases and sVEGFR 
decreases from baseline. In patients with metastatic RCC, 
greater axitinib exposure has also been associated with a 
higher ORR and longer PFS and OS [37]. Other investi-
gators have conducted PK/PD analyses in patients with 
thyroid cancer. For example, motesanib AUCss was a bet-
ter predictor of response than dose [38]. Also, maximum 
pazopanib plasma concentration during the first treat-
ment cycle correlated with maximum change in tumor 
size and was significantly higher in patients who achieved 
responses [19].
Limitations of the present trial included the number of 
patients with indeterminate or missing response assessments 
(n = 14), and the lack of control group and independent 
radiology review of response. Additionally, results for the 
13 patients who continued axitinib for long periods of time 
in the extension study were based on data collected from 
this original trial. The extension study is ongoing and as of 
the cutoff date of June 1, 2012, duration of treatment ranged 
from 2.6 to 7.5 years in eight patients no longer receiv-
ing axitinib and from 6.2 to 7.4 years in five patients still 
receiving axitinib. Although AE data for long-term axitinib 
in the extension study were not yet available, five patients 
still on treatment were receiving total daily axitinib doses of 
6–12 mg (data on file; Pfizer Inc, New York, NY, USA).
Fig. 2  Maximum percent 
change from baseline observed 
at any point during the study 
in the sum of longest diam-
eter (SLD) of target lesions 
relative to axitinib area under 
the plasma concentration–time 
curve at steady-state (AUCss) 
during a cycle 1 (AUCss-cycle1)  
and b the entire time on study 
(AUCss-study); although no 
patients in the study had a 
RECIST-defined complete 
response, two patients had 
target lesions that became 
unmeasurable during axitinib 
treatment (−100 % change)
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In conclusion, axitinib appears to be active in vari-
ous histologic subtypes of advanced thyroid cancer, as 
evidenced by a high ORR and long median duration of 
response, PFS, and OS. A limited number of patients with 
anaplastic histology (n = 2) were enrolled, making defini-
tive conclusions in this subtype impossible. Axitinib also 
demonstrated a generally favorable safety profile. Moreo-
ver, greater axitinib exposure was associated with favora-
ble differences in biomarkers and reduction in tumor size. 
PK/PD analyses suggest that patients with higher axitinib 
exposure were more likely to achieve PR, thereby provid-
ing further rationale for dose increases in patients who tol-
erate the starting dose of 5 mg twice daily without elevated 
BP. Overall, these data suggest axitinib may be useful in 
the treatment of 131I-refractory advanced thyroid cancer, 
and individualized dose titration based on tolerability and 
Fig. 3  Logistic regression analysis of probability of an investigator-
assessed partial response relative to axitinib area under the plasma 
concentration–time curve at steady-state during cycle 1 (AUCss-cycle1)
1200
1000
800
600
%
 C
ha
ng
e 
fro
m
 b
as
el
in
e 
in
 V
EG
F
400
200
0
High AUC
ss-cycle 1Low AUCss-cycle 1
Median
20
0
–20
%
 C
ha
ng
e 
fro
m
 b
as
el
in
e 
in
 s
VE
G
FR
2
–40
–60
High AUC
ss-cycle 1Low AUCss-cycle 1
Median
0 200 400 600 800
0.0
0.2
0.4
0.6
0.8
1.0
% Change from baseline in VEGF 
Pr
op
or
tio
n 
of
 re
sp
on
de
rs
−60 −40 −20 0
0.0
0.2
0.4
0.6
0.8
1.0
% Change from baseline in sVEGFR2 
Pr
op
or
tio
n 
of
 re
sp
on
de
rs
a
b
Fig. 4  a Greatest percent change from baseline per patient at any 
time during the study in vascular endothelial growth factor (VEGF) 
and soluble VEGF receptor 2 (sVEGFR2) in patients with high 
(≥mAUCss-cycle1) and low (<mAUCss-cycle1) exposure to axitinib, and 
b proportion of patients with investigator-assessed partial responses 
in quartiles grouped according to change from baseline in soluble 
proteins. mAUCss-cycle1, median area under the plasma concentration–
time curve at steady-state during cycle 1
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BP assessment is warranted. Larger randomized trials are 
necessary to confirm the role of axitinib for the treatment 
of advanced thyroid cancer.
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